An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Veracyte (NASDAQ: VCYT) will present seven abstracts on its genomic tests for prostate and breast cancers at the ESMO Congress 2022 from September 9-13 in Paris. A notable highlight includes data from a post-hoc analysis of the Decipher Prostate test within the STAMPEDE trial, potentially expanding its use among advanced prostate cancer patients in the U.S. and abroad. Veracyte aims to enhance patient care through its diagnostic tests, which are designed to minimize risky procedures and ensure faster treatment decisions.
Positive
Presentation of seven abstracts at ESMO Congress 2022.
New data from STAMPEDE trial supports Decipher Prostate test expansion.
Plans to offer Decipher Prostate test as an IVD outside the U.S.
Negative
None.
New data support continued expansion of the company’s tests, including determining treatment prognosis in men with advanced prostate cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, 2022, in Paris.
“The abstracts we’ll share at ESMO 2022 reinforce the value our genomic tests bring to physicians diagnosing and treating cancer patients,” said Marc Stapley, Veracyte’s chief executive officer. “We are particularly excited about new data from a post-hoc analysis that evaluated the clinical performance of our Decipher Prostate test in one arm of the large, multi-center, randomized STAMPEDE trial. We believe these data may help expand the Decipher test’s availability to advanced prostate cancer patients in the United States, and also support our plans to offer the Decipher Prostate test as an IVD on the nCounter Analysis System for use outside of the United States where laboratories can perform it locally.”
Following are details of the abstracts that will be shared as part of the ESMO 2022 Congress:
Title:
Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): an ancillary study of the STAMPEDE AAP trial
Presenter:
Marina Perry, PhD, University College London Cancer Institute
Date/Time:
September 11, 2022, 8:40-8:50 a.m. CEST
Presentation #:
1358O
Title:
A Transcriptomic Signature of AR Activity Prognosticates Development of Castration-Resistance following Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer
Presenter:
Phuoc Tran, MD, PhD, University of Maryland School of Medicine
Date/Time:
September 11, 2022
Poster #:
1381P
Title:
Transcriptomic based indicators of potential therapeutic response to targeted therapy among 50,000 men with localized prostate cancer
Presenter:
Edward M. Schaeffer, MD, PhD, Northwestern Medicine
Date/Time:
September 11, 2022
Poster #:
1377P
Title:
Biopsy-based Basal-Luminal Subtyping Classifier in High-risk Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Randomized Phase III Trials
Presenter:
Paul Nguyen, MD, Brigham and Women’s Hospital
Date/Time:
September 11, 2022
Poster #:
1378P
Title:
Transcriptomic-based prognostic and predictive biomarker analysis of ENACT: a randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)
Presenter:
Ashley Ross, MD, PhD, Feinberg School of Medicine at Northwestern University
Date/Time:
September 11, 2022
Poster #:
1385P
Title:
Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa)
Presenter:
M.L.K. Chua, MD, PhD, National Cancer Centre Singapore
Date/Time:
September 11, 2022
Poster #:
1408P
Title:
Current use of breast cancer multigene signatures in clinical practice among European experts: results from the PROCURE Project
Presenter:
Giuseppe Curigliano, MD, PhD, IEO - Istituto Europeo di Oncologia
Date/Time:
September 11, 2022
Poster #:
164P
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. An example of a forward-looking statement includes, among others, that data presented at the ESMO Congress may help expand availability of our Decipher Prostate Genomic Classifier.
Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q to be filed for the three months ended June 30, 2022. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, the Veracyte logo, Decipher and Prosigna are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.
Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.
Media:
Tracy Morris Vice President of Global Corporate Communications tracy.morris@veracyte.com
650-380-4413
Source: Veracyte, Inc.
FAQ
What new data did Veracyte present at the ESMO Congress 2022?
Veracyte presented data from a post-hoc analysis of the Decipher Prostate test within the STAMPEDE trial, which supports its potential use for advanced prostate cancer patients.
When was the ESMO Congress 2022 held?
The ESMO Congress 2022 took place from September 9-13, 2022.
What is the significance of the Decipher Prostate test?
The Decipher Prostate test offers genomic insights that may guide treatment decisions for advanced prostate cancer, potentially improving patient outcomes.
What are Veracyte's future plans for the Decipher Prostate test?
Veracyte plans to expand the availability of the Decipher test in the U.S. and provide it as an IVD on the nCounter Analysis System for international use.
What cancers are mentioned in Veracyte's press release?
The press release mentions genomic tests for prostate and breast cancers.
